Issue 34, 2024

A score and nine years of irbesartan

Abstract

Irbesartan is a non-peptide antagonist of the angiotensin-II-AT1 receptor and is used for the treatment of hypertension. Here, the history, achievements and open questions related to irbesartan are examined. Tautomery of the tetrazole moiety leads to two desmotropes, A and B. Roughly ten dozen data collections on single crystals at various temperatures, from X-rays and neutrons, are presented, deposited and interpreted; new structures are described and a detailed evolution of the thermal expansion is achieved. Disorder of the n-butyl-chains is observed in A and B. The trigonal desmotrope A builds its structure incorporating a hydrate channel upon nucleation. The hydrophobic nature of the n-butyl-chains induces the growth of a flat crown of chains in a meta-stable phase, disappearing after the thermally activated creation of a gauche conformer that distorts this wreath to a more prolate shape. This irreversible, conformational transition leads, henceforth, to a different evolution of lattice parameters and thermal expansion; the water inclusion explains the strained, imperfect crystallites, complex solubilities, a capricious packing coefficient and slow growth. In the triclinic desmotrope B, the all-transgauche disorder in the n-butyl-chain leads to random, diffuse changes in the structure between 265 and 165 K. As confirmed by calorimetry and thermal expansion, these subtle, local re-arrangements do not affect the space group and trigger a reversible, first-order phase transition at 208 K. The neutron study brings desirable clarity regarding the geometry of the tetrazole and its hydrogen, and precious reference values for the weak interactions. Focussing on the tetrazole and the n-butyl-chains, we propose an alternative interpretation of the 15N NMR spectra, published more than two decades earlier.

Graphical abstract: A score and nine years of irbesartan

Supplementary files

Article information

Article type
Paper
Submitted
21 Nov 2023
Accepted
17 May 2024
First published
09 Jul 2024
This article is Open Access
Creative Commons BY license

CrystEngComm, 2024,26, 4566-4578

A score and nine years of irbesartan

P. Ochsenbein, M. Bonin, F. Fadaei-Tirani, M. Lemée, J. Kieffer, D. Görl, M. El-Hajji and K. Schenk-Joß, CrystEngComm, 2024, 26, 4566 DOI: 10.1039/D3CE01172K

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements